Sentences with phrase «current immunotherapy treatment»
To learn more about current immunotherapy treatment options for women with gynecologic cancers, and how close we are to making these treatments available to more patients, watch Dr. Odunsi's webinar from June 4, 2013.
http://cancerresearch.org/
Both memory T cells subtypes can be reactivated with current immunotherapy treatments, and reactivation of both requires DC1 dendritic cells.
Not exact matches
The FDA has approved a four - week dosing schedule for Bristol - Myers Squibb's cancer immunotherapy treatment Opdivo, doubling the current two - week schedule for a variety of cancers.
Much current research in immuno - oncology focuses on improving these treatments, for example, by finding new immunotherapy targets and identifying biomarkers that predict a patient's response.
«If successful,» Zhou said, «all these efforts would remarkably improve the current cancer immunotherapies by personalizing the treatment to exactly where and when it is needed, while reducing side effects.»
According to Shams, if patients have predominant late summer - fall allergy symptoms or fail to respond to ragweed immunotherapy it may prompt further testing and modification of their current treatment regimens.
As Scientific American reported earlier this year, more than half of the current cancer clinical trials do incorporate some form of immunotherapy but still oncologists are often only in the early stages of understanding how to use such treatment on a larger scale.
«Fortunately, the majority of cases respond very well to the current first line treatment, which is a combination of chemotherapy and immunotherapy.
This treatment resistance may be caused by certain anti-NMDA receptor antibody - producing plasma cells that remain inaccessible to current immunotherapies.
Current phase I immunotherapy trials are underway to test the utility of inhibiting Cbl - b in PBMCs in the treatment of cancer patients (ClinicalTrials.gov: NCT02166255, NCT03087591).
Our current efforts relating to our pluripotent stem cell platform are focused on developing AST - OPC1 (hES cell - derived neural cells) for the treatment of spinal cord injury and other neurodegenerative diseases, and AST - VAC2 (hES cell - derived immunotherapy) for cancer.
«Insights derived from these data will be critical to improving the effectiveness of current cancer immunotherapy treatments and developing new immune - based treatment strategies,» said Justin Guinney, Ph.D., principal investigator, director of computational oncology and bioinformatics at Sage Bionetworks.